妊娠35-37周对即将发生的子痫前期的预测
该前瞻性观察研究在英格兰2家产科医院纳入15247例妊娠,于35+0-36+6周检测胎盘生长因子、可溶性fms样酪氨酸激酶-1及平均动脉压,比较三者联合的竞争风险模型与单用胎盘生长因子或可溶性fms样酪氨酸激酶-1/胎盘生长因子比值筛查2周和4周内因子痫前期分娩的性能,联合模型优于后两者。
要点
- 在35+0-36+6周,联合母体因素、胎盘生长因子、可溶性fms样酪氨酸激酶-1和平均动脉压的竞争风险模型筛查2周和4周内因子痫前期分娩优于单用胎盘生长因子或可溶性fms样酪氨酸激酶-1/胎盘生长因子比值。
- 联合模型筛查2周内子痫前期的AUC为0.975,高于单用胎盘生长因子(0.900,P<.0001)和可溶性fms样酪氨酸激酶-1/胎盘生长因子比值(0.932,P=.0001)。
- 在假阳性率2-30%时,联合模型对2周和4周内因子痫前期分娩的检出率较可溶性fms样酪氨酸激酶-1/胎盘生长因子比值约高10%,较单用胎盘生长因子约高20%;3种检测的阴性预测值相似。
核心结论
- 在35+0-36+6周,竞争风险模型筛查即将因子痫前期分娩的性能优于单用胎盘生长因子或可溶性fms样酪氨酸激酶-1/胎盘生长因子比值。
研究设计与样本
- 前瞻性观察研究,纳入英格兰2家产科医院在35+0-36+6周常规产检的15247例妊娠,其中326例(2.1%)随后发生子痫前期。
主要发现
- 筛查2周内因子痫前期分娩的AUC:联合模型0.975(95%CI 0.964-0.985)vs 单用胎盘生长因子0.900(95%CI 0.866-0.935,P<.0001)vs 可溶性fms样酪氨酸激酶-1/胎盘生长因子比值0.932(95%CI 0.904-0.960,P=.0001)。
- 筛查4周内因子痫前期分娩的AUC:联合模型0.907(95%CI 0.886-0.928)vs 单用胎盘生长因子0.827(95%CI 0.800-0.854,P<.0001)vs 可溶性fms样酪氨酸激酶-1/胎盘生长因子比值0.857(95%CI 0.830-0.883,P<.0001)。
- 在假阳性率2-30%时,联合模型对2周和4周内因子痫前期分娩的检出率较可溶性fms样酪氨酸激酶-1/胎盘生长因子比值约高10%,较单用胎盘生长因子约高20%;3种检测的阴性预测值相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the weeks preceding the clinical onset of preeclampsia, the maternal serum level of the angiogenic placental growth factor is decreased and that of the antiangiogenic factor soluble fms-like tyrosine kinase-1 is increased. Women presenting at specialist clinics with signs or symptoms of hypertensive disorders have been stratified according to concentrations of placental growth factor or the ratio of concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor to determine clinical management for the subsequent 1-4 weeks. An alternative approach for the prediction of preeclampsia is use of the competing risks model, a Bayes' theorem based method, to derive patient-specific risk for preeclampsia by various combinations of maternal characteristics and medical history with multiples of the median values of biomarkers. OBJECTIVE: The purpose of this study was to compare the performance of screening for delivery with preeclampsia at ≤2 and ≤4 weeks after assessment at 35+0-36+6 weeks gestation between the use of percentile cut-offs in placental growth factor alone or the soluble fms-like tyrosine kinase-1/placental growth factor ratio and the competing risks model. STUDY DESIGN: This was a prospective observational study in women who attended a routine hospital visit at 35+0-36+6 weeks gestation in 2 maternity hospitals in England. The visits included the recording of maternal demographic characteristics and medical history and the measurement of serum placental growth factor and soluble fms-like tyrosine kinase-1 and mean arterial pressure. The areas under the receiver operating characteristics curves were used to compare the predictive performance for preeclampsia with delivery at ≤2 and ≤4 weeks from assessment of screening by placental growth factor alone and the soluble fms-like tyrosine kinase-1/placental growth factor ratio with that of a previously developed competing risks model with a combination of maternal factors, placental growth factor, soluble fms-like tyrosine kinase-1, and mean arterial pressure (triple test). RESULTS: First, the study population of 15,247 pregnancies included 326 pregnancies (2.1%) that subsequently experienced preeclampsia. Second, in the screening for delivery with preeclampsia at ≤2 and ≤4 weeks from assessment, the performance of the triple test was superior to that of placental growth factor alone or the soluble fms-like tyrosine kinase-1/placental growth factor ratio. The area under the receiver operating characteristics curves for preeclampsia at ≤2 weeks in screening by the triple test (0.975; 95% confidence interval, 0.964-0.985) was higher than that of placental growth factor alone (0.900; 95% confidence interval, 0.866-0.935; P<.0001) and the soluble fms-like tyrosine kinase-1/placental growth factor ratio (0.932; 95% confidence interval, 0.904-0.960; P=.0001). Similarly, the areas under the receiver operating characteristics curves for preeclampsia at ≤4 weeks in screening by the triple test (0.907; 95% confidence interval, 0.886-0.928) was higher than that of placental growth factor alone (0.827; 95% confidence interval, 0.800-0.854; P<.0001) or the soluble fms-like tyrosine kinase-1/placental growth factor ratio (0.857; 95% confidence interval, 0.830-0.883; P<.0001). Third, at most, screen-positive rates of 2-30% the detection rate of delivery with preeclampsia at ≤2 and ≤4 weeks that was achieved by the triple test was approximately 10% higher than that of the soluble fms-like tyrosine kinase-1/placental growth factor ratio and 20% higher than that of placental growth factor alone; the negative predictive value was similar for the 3 tests. CONCLUSION: At 35+0-36+6 weeks gestation, the performance of screening for imminent delivery with preeclampsia by the competing risks model is superior to that of placental growth factor alone or the soluble fms-like tyrosine kinase-1/placental growth factor ratio.
引用
- Ciobanu A, Wright A, Panaitescu A, et al. Prediction of imminent preeclampsia at 35-37 weeks gestation. Am J Obstet Gynecol. 2019. PMID: 30738886. doi:10.1016/j.ajog.2019.01.235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。